ATM is altered in 4.43% of clear cell renal cell carcinoma patients [2].

ATM is an inclusion eligibility criterion in 3 clinical trials for clear cell renal cell carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ATM status and clear cell renal cell carcinoma as inclusion criteria, 3 are phase 2 (3 open) [3].

ATR is altered in 0.58% of clear cell renal cell carcinoma patients [2].

ATR is an inclusion eligibility criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BARD1 is altered in 0.35% of clear cell renal cell carcinoma patients [2].

BARD1 is an inclusion eligibility criterion in 2 clinical trials for clear cell renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BARD1 status and clear cell renal cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

BRCA1 is altered in 0.8% of clear cell renal cell carcinoma patients [2].

BRCA1 is an inclusion eligibility criterion in 2 clinical trials for clear cell renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA1 status and clear cell renal cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

BRCA2 is altered in 3.45% of clear cell renal cell carcinoma patients [2].

BRCA2 is an inclusion eligibility criterion in 2 clinical trials for clear cell renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA2 status and clear cell renal cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

BRIP1 is altered in 0.69% of clear cell renal cell carcinoma patients [2].

BRIP1 is an inclusion eligibility criterion in 2 clinical trials for clear cell renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRIP1 status and clear cell renal cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

CDK12 is altered in 0.44% of clear cell renal cell carcinoma patients [2].

CDK12 is an inclusion eligibility criterion in 2 clinical trials for clear cell renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDK12 status and clear cell renal cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

CHEK1 is altered in 0.35% of clear cell renal cell carcinoma patients [2].

CHEK1 is an inclusion eligibility criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK1 status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CHEK2 is altered in 1.63% of clear cell renal cell carcinoma patients [2].

CHEK2 is an inclusion eligibility criterion in 2 clinical trials for clear cell renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CHEK2 status and clear cell renal cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

FANCA is altered in 2.17% of clear cell renal cell carcinoma patients [2].

FANCA is an inclusion eligibility criterion in 2 clinical trials for clear cell renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FANCA status and clear cell renal cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

FANCB is an inclusion eligibility criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCB status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCC is altered in 1.1% of clear cell renal cell carcinoma patients [2].

FANCC is an inclusion eligibility criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCC status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCD2 is altered in 1.0% of clear cell renal cell carcinoma patients [2].

FANCD2 is an inclusion eligibility criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCD2 status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCE is altered in 0.34% of clear cell renal cell carcinoma patients [2].

FANCE is an inclusion eligibility criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCE status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCF is altered in 1.68% of clear cell renal cell carcinoma patients [2].

FANCF is an inclusion eligibility criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCF status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCG is altered in 0.66% of clear cell renal cell carcinoma patients [2].

FANCG is an inclusion eligibility criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCG status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCI is altered in 2.78% of clear cell renal cell carcinoma patients [2].

FANCI is an inclusion eligibility criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCI status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCL is an inclusion eligibility criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCL status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCM is altered in 4.04% of clear cell renal cell carcinoma patients [2].

FANCM is an inclusion eligibility criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCM status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FH is altered in 0.69% of clear cell renal cell carcinoma patients [2].

FH is an inclusion eligibility criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FH status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

IDH1 is altered in 0.13% of clear cell renal cell carcinoma patients [2].

IDH1 is an inclusion eligibility criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains IDH1 status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

IDH2 is altered in 0.67% of clear cell renal cell carcinoma patients [2].

IDH2 is an inclusion eligibility criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains IDH2 status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KRAS is altered in 0.25% of clear cell renal cell carcinoma patients [2].

KRAS is an inclusion eligibility criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KRAS status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MCPH1 is an inclusion eligibility criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MCPH1 status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MRE11A is altered in 0.69% of clear cell renal cell carcinoma patients [2].

MRE11A is an inclusion eligibility criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MRE11A status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MYC is altered in 0.68% of clear cell renal cell carcinoma patients [2].

MYC is an inclusion eligibility criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NBN is altered in 1.12% of clear cell renal cell carcinoma patients [2].

NBN is an inclusion eligibility criterion in 2 clinical trials for clear cell renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NBN status and clear cell renal cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

PALB2 is altered in 1.49% of clear cell renal cell carcinoma patients [2].

PALB2 is an inclusion eligibility criterion in 2 clinical trials for clear cell renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PALB2 status and clear cell renal cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

PTEN is altered in 5.57% of clear cell renal cell carcinoma patients [2].

PTEN is an inclusion eligibility criterion in 2 clinical trials for clear cell renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

RAD50 is altered in 1.55% of clear cell renal cell carcinoma patients [2].

RAD50 is an inclusion eligibility criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD51 is altered in 0.41% of clear cell renal cell carcinoma patients [2].

RAD51 is an inclusion eligibility criterion in 2 clinical trials for clear cell renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51 status and clear cell renal cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

RAD51B is an inclusion eligibility criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD51C is altered in 0.18% of clear cell renal cell carcinoma patients [2].

RAD51C is an inclusion eligibility criterion in 2 clinical trials for clear cell renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51C status and clear cell renal cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

RAD51D is altered in 0.18% of clear cell renal cell carcinoma patients [2].

RAD51D is an inclusion eligibility criterion in 2 clinical trials for clear cell renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51D status and clear cell renal cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

RAD54L is altered in 0.23% of clear cell renal cell carcinoma patients [2].

RAD54L is an inclusion eligibility criterion in 2 clinical trials for clear cell renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD54L status and clear cell renal cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

RB1 is altered in 0.51% of clear cell renal cell carcinoma patients [2].

RB1 is an inclusion eligibility criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RB1 status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

SDHA is altered in 1.48% of clear cell renal cell carcinoma patients [2].

SDHA is an inclusion eligibility criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SDHA status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SDHB is altered in 0.97% of clear cell renal cell carcinoma patients [2].

SDHB is an inclusion eligibility criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SDHB status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SDHC is altered in 0.28% of clear cell renal cell carcinoma patients [2].

SDHC is an inclusion eligibility criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SDHC status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SDHD is altered in 0.28% of clear cell renal cell carcinoma patients [2].

SDHD is an inclusion eligibility criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SDHD status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SETD2 is altered in 27.53% of clear cell renal cell carcinoma patients [2].

SETD2 is an inclusion eligibility criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SETD2 status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SLX4 is altered in 0.67% of clear cell renal cell carcinoma patients [2].

SLX4 is an inclusion eligibility criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SLX4 status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TP53 is altered in 9.95% of clear cell renal cell carcinoma patients [2].

TP53 is an inclusion eligibility criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].